96314-28-2

Basic information

• Product Name: (2S,4R)-1-(tert-butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic acid
• Synonyms: (2S,4R)-1-(tert-butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic acid;(2S,4R)-4-[[(4-Methylphenyl)sulfonyl]oxy]-1,2-pyrrolidinedicarboxylic acid 1-(tert-butyl) ester;1,2-Pyrrolidinedicarboxylic acid, 4-[[(4-Methylphenyl)sulfonyl]oxy]-, 1-(1,1-diMethylethyl) ester, (2S,4R)-
• CAS NO: 96314-28-2
• Molecular Formula: C₁₇H₂₃NO₇S
• Molecular Weight: 385.435
• Mol File: 96314-28-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 138-139℃
• Boiling Point: 553.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.36
• PKA: 3.54±0.40(Predicted)
• CAS DataBase Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-(tert-butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic acid(96314-28-2)
• EPA Substance Registry System: (2S,4R)-1-(tert-butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic acid(96314-28-2)

Safety Data

• Hazardous Substances Data: 96314-28-2(Hazardous Substances Data)

Usage

Uses

(2S,4R)-1-(tert-Butoxycarbonyl)-4-(tosyloxy)pyrrolidine-2-carboxylic Acid is an intermediate in the synthesis of Fosinopril-d5 Sodium Salt (F727803), the labeled analogue of Fosinopril Sodium Salt (F727800), a phosphinic acid containing angiotensin converting enzyme (ACE) inhibitor. Antihypertensive.

Upstream product

• 96314-27-1 benzyl (2S,4R)-1-tert-butoxycarbonyl-4-[(4-methylbenzenesulfonyl)oxy]-2-pyrrolidinecarboxylate 
• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 87691-27-8 N-tert-butoxycarbonyl-L-cis-4-hydroxyproline 
• 153790-69-3 (2S,4R)-<4-2H1>-proline 
• 153790-67-1 N-Boc-D-cis-4-(p-toluenesulfonyloxy)proline 
• 51-35-4 4R-4-hydroxyproline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 89813-47-8 N-(tert-butoxycarbonyl)-(2S,4R)-4-hydroxyproline benzyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 88043-21-4 (2S,4R)-4-(toluene-4-sulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 103290-39-7 (2R,4S)-1-(tert-butoxycarbonyl)-4-phenylpyrrolidine-2-carboxylic acid 
• 103290-39-7 (2S,4S)-1-(tert-butoxycarbonyl)-4-phenyl-2-pyrrolidinecarboxylic acid 
• 802911-23-5 (2S,4R)-(N-tert-butyloxycarbonyl)-4-(Z)-propenylproline 
• 540501-62-0 (2S,4S)-N-tert-butyloxycarbonyl-4-propylproline 

Relevant articles and documents

Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs

Inhibitors of CDK4 and CDK6 have emerged as important FDA-approved treatment options for breast cancer patients. The properties and pharmacology of CDK4/6 inhibitor medicines have been extensively profiled, and investigations into the degradation of these

LITHIUM DIPHENYLCUPRATE REACTIONS WITH 4-TOSYLOXY-L-PROLINES; AN INTERESTING STEREOCHEMICAL OUTCOME. A SYNTHESIS OF TRANS-4-PHENYL-L-PROLINE.

The reaction of lithium diphenylcuprate with trans-4- and cis-4-tosyloxy-L-prolines gives excellent yields of 4-phenyl substituted L-prolines and the reaction proceeds with net retention of configuration at the carbon center bearing the tosyloxy group.